Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Seiichiro Katagiri, MD PhD, Tetsuzo Tauchi, MD PhD, Yuu Saito, MD, Tamiko Sugro, MD, Michiyo Asano, MD, Seiichiro Yoshizawa, MD PhD, Juri Sakuta, MD PhD, Daigo Akahane, MD PhD, Yuko Tanaka, MD PhD, Nahoko Furuya, MD PhD, Keiko Ando, MD PhD, Hiroaki Fujimoto, MD, Seiichi Okabe, MD PhD, Moritaka Gotoh, MD PhD, Yoshikazu Ito, MD PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2014) 124 (21): 1797.

https://doi.org/10.1182/blood.V124.21.1797.1797

Published: 2014

Journal Articles

Lower Plasma Mir-92a Levels Predict Shorter Progression-Free Survival In Newly Diagnosed Symptomatic Multiple Myeloma Patients

Seiichiro Yoshizawa, MD, PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD, PhD, Shinsuke Iida, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 1879.

https://doi.org/10.1182/blood.V122.21.1879.1879

Published: 2013

Journal Articles

Therapeutic Potential Of Targeting Sphingosine-1-Phosuphate and Sphingosine Kinases In Multiple Myeloma

Yuko Tanaka, MD, Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yoshikazu Ito, MD, PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 1894.

https://doi.org/10.1182/blood.V122.21.1894.1894

Published: 2013

Journal Articles

High Frequencies Of Switching To 2 nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants

Seiichiro Katagiri, MD, Tetsuzo Tauchi, MD, Tomohiro Umezu, PhD, Kazuhiro Ohtsuki, PhD, Kenichi Tadokoro, Yoshinori Yamamoto, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 4021.

https://doi.org/10.1182/blood.V122.21.4021.4021

Published: 2013

Journal Articles

Activation Levels of Natural Killer Cells and CD8 + T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients

Seiichiro Katagiri, MD, Izuru Mizoguchi, PhD, Takayuki Yoshimoto, PhD, Junichiro Mizuguchi, MD, PhD, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 3745.

https://doi.org/10.1182/blood.V120.21.3745.3745

Published: 2012

Journal Articles

Plasma Mir-92a Levels in Multiple Myeloma Correlate with T-Cell-Derived Mir-92a and Restored in Bortezomib Responder

Sei-ichiro Yoshizawa, MD, Junko H Ohyashiki, MD, PhD, Michiyo Ohyashiki, MD, Tomohiro Umezu, PhD, Kenshi Suzuki, MD, PhD, Atsushi Inagaki, MD, PhD, Shinsuke Iida, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 2871.

https://doi.org/10.1182/blood.V118.21.2871.2871

Published: 2011

Journal Articles

Age-Related Decrease of Human CD8 + T-Cell Mir-92a Level Correlated with Reduction of naïve T Lymphocyte

Michiyo Ohyashiki, MD, Junko H Ohyashiki, MD, PhD, Ayako Hirota, Chiaki Kobayashi, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 2186.

https://doi.org/10.1182/blood.V118.21.2186.2186

Published: 2011

Journal Articles

Increased NK Cells and Decreased CD3 + CD8 + CD62L + T Cells in CML Patients Who Sustained Complete Molecular Remission After Discontinuation of Imatinib

Kazuma Ohyashiki, MD, PhD, Sei-ichiro Katagiri, MD, Tetsuzo Tauchi, MD, PhD, Junko H Ohyashiki, MD, PhD, Yasuhiro Maeda, MD, PhD, Itaru Matsumura, MD, PhD, Taiichi Kyo, MD

Blood (2011) 118 (21): 1697.

https://doi.org/10.1182/blood.V118.21.1697.1697

Published: 2011

NARROW

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Lower Plasma Mir-92a Levels Predict Shorter Progression-Free Survival In Newly Diagnosed Symptomatic Multiple Myeloma Patients

Therapeutic Potential Of Targeting Sphingosine-1-Phosuphate and Sphingosine Kinases In Multiple Myeloma

High Frequencies Of Switching To 2 nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants

Activation Levels of Natural Killer Cells and CD8 + T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients

Plasma Mir-92a Levels in Multiple Myeloma Correlate with T-Cell-Derived Mir-92a and Restored in Bortezomib Responder

Age-Related Decrease of Human CD8 + T-Cell Mir-92a Level Correlated with Reduction of naïve T Lymphocyte

Increased NK Cells and Decreased CD3 + CD8 + CD62L + T Cells in CML Patients Who Sustained Complete Molecular Remission After Discontinuation of Imatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only